Trial Outcomes & Findings for Medico-economic Evaluation of IMRT by Hi Art, RapidArc, VMAT Therapy in Prostate, Cervix and Anal Canal Cancers (NCT NCT01325961)
NCT ID: NCT01325961
Last Updated: 2026-07-02
Results Overview
Total: Costs of the devices, maintenance costs ; personnel costs directly related to the medical therapeutic procedure (physicians, medical physicists, dosimetry technicians), for the 3 ways of radiotherapy using: Rapid Arc, HT and VMAT
Recruitment status
COMPLETED
Study phase
NA
Target enrollment
215 participants
Primary outcome timeframe
2 months
Results posted on
2026-07-02
Participant Flow
Participant milestones
| Measure |
Prostate-Rapid Arc
IMRT using Rapid Arc for prostate patients
|
Prostate-HT
IMRT using HT for prostate patients
|
Prostate-VMAT
IMRT using VMAT for prostate patients
|
Anal Canal-Rapid Arc
IMRT using Rapid Arc for Anal canal patients
|
Anal Canal-HT
IMRT using HT for Anal canal patients
|
Anal Canal-VMAT
IMRT using VMAT for Anal canal patients
|
Cervix-Rapid Arc
IMRT using Rapid Arc for cervix patients
|
Cervix-HT
IMRT using HT for cervix patients
|
Cervix-VMAT
IMRT using VMAT for cervix patients
|
|---|---|---|---|---|---|---|---|---|---|
|
Overall Study
STARTED
|
89
|
49
|
17
|
7
|
13
|
10
|
10
|
17
|
3
|
|
Overall Study
COMPLETED
|
89
|
49
|
17
|
7
|
13
|
10
|
10
|
17
|
3
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
Medico-economic Evaluation of IMRT by Hi Art, RapidArc, VMAT Therapy in Prostate, Cervix and Anal Canal Cancers
Baseline characteristics by cohort
| Measure |
Prostate-Rapid Arc
n=89 Participants
IMRT using Rapid Arc for prostate patients
|
Prostate-HT
n=49 Participants
IMRT using HT for prostate patients
|
Prostate-VMAT
n=17 Participants
IMRT using VMAT for prostate patients
|
Anal Canal-Rapid Arc
n=7 Participants
IMRT using Rapid Arc for Anal canal patients
|
Anal Canal-HT
n=13 Participants
IMRT using HT for Anal canal patients
|
Anal Canal-VMAT
n=10 Participants
IMRT using VMAT for Anal canal patients
|
Cervix-Rapid Arc
n=10 Participants
IMRT using Rapid Arc for cervix patients
|
Cervix-HT
n=17 Participants
IMRT using HT for cervix patients
|
Cervix-VMAT
n=3 Participants
IMRT using VMAT for cervix patients
|
Total
n=215 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Age, Categorical
Between 18 and 65 years
|
31 Participants
n=20 Participants
|
16 Participants
n=20 Participants
|
4 Participants
n=40 Participants
|
6 Participants
n=5 Participants
|
7 Participants
n=9 Participants
|
6 Participants
n=6 Participants
|
10 Participants
n=6 Participants
|
16 Participants
n=6 Participants
|
3 Participants
n=5 Participants
|
99 Participants
n=6 Participants
|
|
Age, Categorical
<=18 years
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=9 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=5 Participants
|
0 Participants
n=6 Participants
|
|
Age, Categorical
>=65 years
|
58 Participants
n=20 Participants
|
33 Participants
n=20 Participants
|
13 Participants
n=40 Participants
|
1 Participants
n=5 Participants
|
6 Participants
n=9 Participants
|
4 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
1 Participants
n=6 Participants
|
0 Participants
n=5 Participants
|
116 Participants
n=6 Participants
|
|
Sex: Female, Male
Female
|
0 Participants
n=20 Participants
|
0 Participants
n=20 Participants
|
0 Participants
n=40 Participants
|
5 Participants
n=5 Participants
|
11 Participants
n=9 Participants
|
8 Participants
n=6 Participants
|
10 Participants
n=6 Participants
|
17 Participants
n=6 Participants
|
3 Participants
n=5 Participants
|
54 Participants
n=6 Participants
|
|
Sex: Female, Male
Male
|
89 Participants
n=20 Participants
|
49 Participants
n=20 Participants
|
17 Participants
n=40 Participants
|
2 Participants
n=5 Participants
|
2 Participants
n=9 Participants
|
2 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=6 Participants
|
0 Participants
n=5 Participants
|
161 Participants
n=6 Participants
|
|
Region of Enrollment
France
|
89 participants
n=20 Participants
|
49 participants
n=20 Participants
|
17 participants
n=40 Participants
|
7 participants
n=5 Participants
|
13 participants
n=9 Participants
|
10 participants
n=6 Participants
|
10 participants
n=6 Participants
|
17 participants
n=6 Participants
|
3 participants
n=5 Participants
|
215 participants
n=6 Participants
|
PRIMARY outcome
Timeframe: 2 monthsTotal: Costs of the devices, maintenance costs ; personnel costs directly related to the medical therapeutic procedure (physicians, medical physicists, dosimetry technicians), for the 3 ways of radiotherapy using: Rapid Arc, HT and VMAT
Outcome measures
| Measure |
Cervix Cancer-VMAT
n=3 Participants
IMRT using VMAT for cervix patients
|
Prostate-Rapid Arc
n=89 Participants
IMRT using Rapid Arc for prostate patients
|
Prostate-HT
n=49 Participants
IMRT using HT for prostate patients
|
Prostate-VMAT
n=17 Participants
IMRT using VMAT for prostate patients
|
Anal Canal-Rapid Arc
n=7 Participants
IMRT using Rapid Arc for Anal canal patients
|
Anal Canal-HT
n=13 Participants
IMRT using HT for Anal canal patients
|
Anal Canal-VMAT
n=10 Participants
IMRT using VMAT for Anal canal patients
|
Cervix Cancer-Rapid Arc
n=10 Participants
IMRT using Rapid Arc for cervix patients
|
Cervix Cancer-HT
n=17 Participants
IMRT using HT for cervix patients
|
|---|---|---|---|---|---|---|---|---|---|
|
Medico-economic Study : Medical Cost Differential Between 3 Ways of Radiotherapy by IMRT Using Helical Tomotherapy (HT), Dynamic Arc Therapy (Rapid ARC) or Volumetric Modulated Arc Therapy (VMAT)
|
2477.1 EUROS
Standard Deviation 1085.3
|
2400.6 EUROS
Standard Deviation 651.1
|
2793.1 EUROS
Standard Deviation 893.6
|
2615.7 EUROS
Standard Deviation 409.6
|
2383.7 EUROS
Standard Deviation 222.6
|
7014.5 EUROS
Standard Deviation 2961.5
|
3098.5 EUROS
Standard Deviation 312.4
|
1424.1 EUROS
Standard Deviation 597.4
|
5177.4 EUROS
Standard Deviation 2586.4
|
SECONDARY outcome
Timeframe: 3 Monthsthe estimation of the cost differential by individualizing the planning costs and session costs
Outcome measures
| Measure |
Cervix Cancer-VMAT
n=3 Participants
IMRT using VMAT for cervix patients
|
Prostate-Rapid Arc
n=89 Participants
IMRT using Rapid Arc for prostate patients
|
Prostate-HT
n=49 Participants
IMRT using HT for prostate patients
|
Prostate-VMAT
n=17 Participants
IMRT using VMAT for prostate patients
|
Anal Canal-Rapid Arc
n=7 Participants
IMRT using Rapid Arc for Anal canal patients
|
Anal Canal-HT
n=13 Participants
IMRT using HT for Anal canal patients
|
Anal Canal-VMAT
n=10 Participants
IMRT using VMAT for Anal canal patients
|
Cervix Cancer-Rapid Arc
n=10 Participants
IMRT using Rapid Arc for cervix patients
|
Cervix Cancer-HT
n=17 Participants
IMRT using HT for cervix patients
|
|---|---|---|---|---|---|---|---|---|---|
|
Others Economic Criteria
sessions costs
|
2042.5 EUROS
Standard Deviation 874.9
|
1812.4 EUROS
Standard Deviation 520.4
|
2655.9 EUROS
Standard Deviation 852.7
|
2287.4 EUROS
Standard Deviation 380.2
|
1529.4 EUROS
Standard Deviation 194.6
|
6613.4 EUROS
Standard Deviation 2901.7
|
2405.3 EUROS
Standard Deviation 296.7
|
974.2 EUROS
Standard Deviation 567.4
|
4725.6 EUROS
Standard Deviation 2596.4
|
|
Others Economic Criteria
Planning costs
|
434.6 EUROS
Standard Deviation 213.0
|
588.2 EUROS
Standard Deviation 288.2
|
137.2 EUROS
Standard Deviation 117.3
|
328.3 EUROS
Standard Deviation 289.7
|
854.4 EUROS
Standard Deviation 126.0
|
401.1 EUROS
Standard Deviation 116.6
|
693.2 EUROS
Standard Deviation 140.9
|
449.8 EUROS
Standard Deviation 146.7
|
451.8 EUROS
Standard Deviation 91.5
|
SECONDARY outcome
Timeframe: 12 monthsAssess oncological results : Relapse Free Survival (RFS) at 12 months
Outcome measures
| Measure |
Cervix Cancer-VMAT
n=3 Participants
IMRT using VMAT for cervix patients
|
Prostate-Rapid Arc
n=89 Participants
IMRT using Rapid Arc for prostate patients
|
Prostate-HT
n=49 Participants
IMRT using HT for prostate patients
|
Prostate-VMAT
n=17 Participants
IMRT using VMAT for prostate patients
|
Anal Canal-Rapid Arc
n=7 Participants
IMRT using Rapid Arc for Anal canal patients
|
Anal Canal-HT
n=13 Participants
IMRT using HT for Anal canal patients
|
Anal Canal-VMAT
n=10 Participants
IMRT using VMAT for Anal canal patients
|
Cervix Cancer-Rapid Arc
n=10 Participants
IMRT using Rapid Arc for cervix patients
|
Cervix Cancer-HT
n=17 Participants
IMRT using HT for cervix patients
|
|---|---|---|---|---|---|---|---|---|---|
|
Clinical Response of the Treatment by Radiotherapy
|
100.0 Percentage of survival
Interval 100.0 to 100.0
|
97.7 Percentage of survival
Interval 94.5 to 100.0
|
100.0 Percentage of survival
Interval 100.0 to 100.0
|
100.0 Percentage of survival
Interval 100.0 to 100.0
|
100.0 Percentage of survival
Interval 100.0 to 100.0
|
84.6 Percentage of survival
Interval 67.1 to 100.0
|
90.0 Percentage of survival
Interval 73.2 to 100.0
|
70.0 Percentage of survival
Interval 46.7 to 100.0
|
69.3 Percentage of survival
Interval 50.1 to 95.9
|
Adverse Events
Prostate-Rapid Arc
Serious events: 1 serious events
Other events: 80 other events
Deaths: 9 deaths
Prostate-HT
Serious events: 3 serious events
Other events: 48 other events
Deaths: 4 deaths
Prostate-VMAT
Serious events: 0 serious events
Other events: 17 other events
Deaths: 3 deaths
Anal Canal-Rapid Arc
Serious events: 0 serious events
Other events: 7 other events
Deaths: 0 deaths
Anal Canal-HT
Serious events: 3 serious events
Other events: 11 other events
Deaths: 1 deaths
Anal Canal-VMAT
Serious events: 2 serious events
Other events: 10 other events
Deaths: 1 deaths
Cervix-Rapid Arc
Serious events: 1 serious events
Other events: 10 other events
Deaths: 2 deaths
Cervix-HT
Serious events: 0 serious events
Other events: 14 other events
Deaths: 2 deaths
Cervix-VMAT
Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Prostate-Rapid Arc
n=89 participants at risk
IMRT using Rapid Arc for prostate patients
|
Prostate-HT
n=49 participants at risk
IMRT using HT for prostate patients
|
Prostate-VMAT
n=17 participants at risk
IMRT using VMAT for prostate patients
|
Anal Canal-Rapid Arc
n=7 participants at risk
IMRT using Rapid Arc for Anal canal patients
|
Anal Canal-HT
n=13 participants at risk
IMRT using HT for Anal canal patients
|
Anal Canal-VMAT
n=10 participants at risk
IMRT using VMAT for Anal canal patients
|
Cervix-Rapid Arc
n=10 participants at risk
IMRT using Rapid Arc for cervix patients
|
Cervix-HT
n=17 participants at risk
IMRT using HT for cervix patients
|
Cervix-VMAT
n=3 participants at risk
IMRT using VMAT for cervix patients
|
|---|---|---|---|---|---|---|---|---|---|
|
Renal and urinary disorders
Dysuria
|
1.1%
1/89 • Number of events 1 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
2.0%
1/49 • Number of events 1 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/7 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/13 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/3 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
|
Cardiac disorders
decompensated congestive heart failure
|
0.00%
0/89 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
2.0%
1/49 • Number of events 1 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/7 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/13 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/3 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
|
Renal and urinary disorders
Ureteric calculus
|
0.00%
0/89 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
2.0%
1/49 • Number of events 1 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/7 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/13 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/3 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
|
Gastrointestinal disorders
Rectitis
|
1.1%
1/89 • Number of events 1 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/49 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/7 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/13 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/3 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
|
Gastrointestinal disorders
Fistula
|
0.00%
0/89 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/49 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/7 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
7.7%
1/13 • Number of events 1 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/3 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
|
Blood and lymphatic system disorders
NEUTROPENIA
|
0.00%
0/89 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/49 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/7 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
7.7%
1/13 • Number of events 1 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/3 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
|
Renal and urinary disorders
POLLAKIURIA
|
0.00%
0/89 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/49 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/7 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
7.7%
1/13 • Number of events 1 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/3 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
|
Infections and infestations
URINARY INFECTION
|
0.00%
0/89 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/49 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/7 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/13 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
10.0%
1/10 • Number of events 1 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/3 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
|
Blood and lymphatic system disorders
ANEMIA
|
0.00%
0/89 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/49 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/7 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/13 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
10.0%
1/10 • Number of events 1 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/3 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
|
Gastrointestinal disorders
DIARRHEA
|
0.00%
0/89 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/49 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/7 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/13 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
10.0%
1/10 • Number of events 1 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
10.0%
1/10 • Number of events 1 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/3 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
|
General disorders
FEVER
|
0.00%
0/89 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/49 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/7 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/13 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
10.0%
1/10 • Number of events 1 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/3 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
|
Immune system disorders
ALLERGY
|
0.00%
0/89 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/49 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/7 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/13 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
10.0%
1/10 • Number of events 1 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/3 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY EMBOLISM
|
0.00%
0/89 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/49 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/7 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/13 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
10.0%
1/10 • Number of events 1 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/3 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
|
Gastrointestinal disorders
GASTRITIS
|
0.00%
0/89 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/49 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/7 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/13 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
10.0%
1/10 • Number of events 1 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/3 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
Other adverse events
| Measure |
Prostate-Rapid Arc
n=89 participants at risk
IMRT using Rapid Arc for prostate patients
|
Prostate-HT
n=49 participants at risk
IMRT using HT for prostate patients
|
Prostate-VMAT
n=17 participants at risk
IMRT using VMAT for prostate patients
|
Anal Canal-Rapid Arc
n=7 participants at risk
IMRT using Rapid Arc for Anal canal patients
|
Anal Canal-HT
n=13 participants at risk
IMRT using HT for Anal canal patients
|
Anal Canal-VMAT
n=10 participants at risk
IMRT using VMAT for Anal canal patients
|
Cervix-Rapid Arc
n=10 participants at risk
IMRT using Rapid Arc for cervix patients
|
Cervix-HT
n=17 participants at risk
IMRT using HT for cervix patients
|
Cervix-VMAT
n=3 participants at risk
IMRT using VMAT for cervix patients
|
|---|---|---|---|---|---|---|---|---|---|
|
Gastrointestinal disorders
Acute gastrointestinal toxicity
|
74.2%
66/89 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
71.4%
35/49 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
88.2%
15/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
100.0%
7/7 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
76.9%
10/13 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
100.0%
10/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
80.0%
8/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
64.7%
11/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
33.3%
1/3 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
|
Renal and urinary disorders
Acute Genitourinary toxicity
|
79.8%
71/89 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
85.7%
42/49 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
100.0%
17/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
71.4%
5/7 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
38.5%
5/13 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
60.0%
6/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
50.0%
5/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
47.1%
8/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
33.3%
1/3 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
|
Reproductive system and breast disorders
Sexual toxicity
|
50.6%
45/89 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
32.7%
16/49 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
23.5%
4/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
42.9%
3/7 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/13 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
50.0%
5/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
20.0%
2/10 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
17.6%
3/17 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
0.00%
0/3 • Adverse events and serious adverse events has been collected during 60 months after treatment
|
Additional Information
Pr Stéphane SUPIOT
Institut de Cancérologie de l'Ouest (ICO)
Phone: +33 2 40 67 99 00
Email: [email protected]
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place